• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

The Cigna Group Announces Leadership Changes, Expansion Across Subsidiaries

News
Article

The healthcare company will add new members to their teams while others expand their roles, and some retire from them.

A new year brings new moves for The Cigna Group who just announced they are making leadership changes aimed at boosting growth across their subsidiaries Evernorth Health Services and Cigna Healthcare.

Shared in a release January 17, the healthcare company will add new members to their teams while others expand their roles, and some retire from them.

Dennison ©linkedin

Dennison ©linkedin

Within The Cigna Group, Ann Dennison, CPA, will take on the role as deputy chief financial officer (CFO). Previously, Dennison was an executive vice president and the chief financial officer at Nasdaq, where she led a global team responsible for corporate finance, treasury, planning and analysis, investor relations, ESG reporting, procurement, and real estate.

Evanko ©linkedin

Evanko ©linkedin

Dennison will also work under current Cigna Group CFO, Brian Evanko, who will now be taking on the new role of president and chief executive officer of Cigna Healthcare. Evanko will oversee all Cigna Healthcare businesses, including U.S. Commercial, International Health, and U.S. Government.

Palmer ©linkedin

Palmer ©linkedin

The last addition to The Cigna Group is Eric Palmer who will expand his role to assume oversight of the Group’s Enterprise Strategy and Corporate Development. Palmer will continue to serve as president and CEO of Evernorth Health Services.

Holgerson ©linkedin

Holgerson ©linkedin

At Cigna Healthcare, Bryan Holgerson will be promoted to serve as president of U.S. Commercial by the end of 2024 once the current position is completed by Mike Triplett. Triplett plans to retire the position by the end of the year, but then transition to a new role of special advisor to the CEO where he’ll focus on solutions for key distribution channels.

Triplett ©TheCignaGroup.com

Triplett ©TheCignaGroup.com

While The Cigna Group implements these changes, its private foundation, The Cigna Group Foundation, continues to support the community and its children by promoting healthier habits, and focusing on the well-being of the Group itself.

In December 2023, The Cigna Group Foundation pledged almost $3.3 million to address food insecurity and enhance youth mental health, as part of its Healthier Kids For Our Future initiative that has granted $25 million to nearly 150 nonprofits in the U.S. since 2019.

Additionally, The Group’s Board of Directors agreed to spend $10 billion more on buying back their own company shares in December, bringing the company's total share repurchase authority to $11.3 billion.

In 2024, they plan to spend most of their extra funds on this buyback, more specifically, at least $5 billion on buying their own company's shares by mid-2024.

Some of this will happen quickly in the first quarter of 2024 through their accelerated share repurchase program.

Related Videos
Video 1 - "Demodex Blepharitis: Prevalence, Symptoms, Quality of Life Impact, and Diagnosis"
Video 2 - "The Role of Ruxolitinib in Managing Hydroxyurea Resistance or Intolerance"
Video 1 - "Prevalence and Impact of Hydroxyurea Intolerance or Resistance in Polycythemia Vera"
Video 8 - "Risk and Value-Based Contracting for Prescription Drug Therapeutics and Manufacturer’s Support in Utilization"
Video 7 - "Prescribing Prescription Drug Therapeutics: Factors for Providers and Payers to Consider"
Video 9 -"Overcoming Implementation Barriers for Digital Therapeutics Adoption"
Related Content
© 2024 MJH Life Sciences

All rights reserved.